SCHEMBL10195037

SCHEMBL10195037

Cc1cccc2[nH]nc(-c3cn(-c4ccc(C(=O)N5CCOCC5)cc4)nn3)c12

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 1/20 0.45
HPGD P15428 5/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
HTT P42858 2/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LRRK2 Q5S007 2/20 0.43
FLT3 P36888 2/20 0.43
ABL1 P00519 3/20 0.42
BCR P11274 3/20 0.42
ATM Q13315 1/20 0.42
JAK2 O60674 1/20 0.41
PIK3CA P42336 1/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPK14 Q16539 1/20 0.39
DDX3X O00571 1/20 0.39
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10196689 0.89 MAPK10 (0.45) MAPK10HPGDALDH1A1MAPTHTT
SCHEMBL10194768 0.85 FLT3 (0.55) MAPK10HPGDALDH1A1MAPTLRRK2
SCHEMBL10194705 0.83 JAK2 (0.45) MAPK10HPGDALDH1A1MAPTHTT
SCHEMBL10194781 0.83 JAK2 (0.49) MAPK10HPGDALDH1A1MAPTHTT
SCHEMBL10196821 0.80 JAK2 (0.46) MAPK10HPGDALDH1A1MAPTHTT
SCHEMBL10194923 0.80 JAK2 (0.44) MAPK10HPGDALDH1A1MAPTHTT
SCHEMBL10194763 0.80 JAK2 (0.50) MAPK10HPGDALDH1A1MAPTHTT
SCHEMBL10194760 0.79 KMT2A (0.43) MAPK10HPGDALDH1A1MAPTHTT
SCHEMBL10194762 0.79 ABL1 (0.45) MAPK10ALDH1A1KDM4ELRRK2FLT3
SCHEMBL10194757 0.79 JAK2 (0.49) MAPK10ALDH1A1KDM4ELRRK2FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655357-B1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO SA (CH) 2016-06-22 EP disclosed
US-9073892-B2 Indazolyl triazol derivatives MERCK SERONO S.A. (CH) 2015-07-07 US disclosed
US-9073892-B2 Indazolyl triazol derivatives MERCK SERONO S.A. (CH) 2015-07-07 US disclosed
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) 2013-10-17 US disclosed
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) 2013-10-17 US disclosed
WO-2012084704-A1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO S.A. (CH) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274241-A1 INDAZOLYL TRIAZOL DERIVATIVES NFATC1, IL5, CD4 MAPK10 1774/4885HPGD 1495/4885ALDH1A1 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.